Nightingale Health and Boston Heart Diagnostics have successfully completed their pilot and move to the production phase expanding the use of Nightingale’s Health Check in the US
Nightingale Health Plc
Press release
30 October 2024 at 09:35 a.m. (EET)
Nightingale Health Plc’s US subsidiary Nightingale Health United States Inc. (“Nightingale Health”) and Boston Heart Diagnostics Corporation (“Boston Heart”) have successfully completed the pilot announced in June, and have signed an agreement to start providing Nightingale’s blood test based Health Check to Boston Heart’s customers.
Boston Heart is an innovative heart health focused company that provides a leading, advanced diagnostics platform to help identify and reduce the risk of cardiovascular disease, diabetes, and other chronic conditions which impose large costs on the US healthcare system. Headquartered in Massachusetts, Boston Heart offers diagnostic testing to drive a personalized approach to improve patient health and complex chronic disease management. In the partnership the parties make Nightingale Health’s innovative solutions available in the US market, with Boston Heart acting as the seller and distributor of the testing to healthcare providers.
The partnership commenced with a pilot in which Nightingale’s Health Check service was provided to one of Boston Heart’s customers. Now, after successfully completing the pilot during the summer, the parties have agreed on a commercial service model that makes Nightingale Health’s blood test based Health Check widely available for Boston Heart’s customers. The Health Check test identifies risk across 8 common chronic diseases with equal or better performance than current routinely used clinical disease risk assessment tools for myocardial infarction, cardiovascular diseases, type 2 diabetes, liver fibrosis and cirrhosis, chronic kidney disease, COPD, lung cancer and alcoholic liver disease. In addition, Health Check includes 39 commonly used blood markers. All the disease risks and blood markers are provided from a single small-volume blood sample and only age and sex are required as clinical parameters.
“We are pleased to see the positive reception of Nightingale's Health Check in the pilot phase. We are delighted to continue the strong partnership with Boston Heart and excited to move our service from pilot to the production phase. Nightingale's Health Check is the world-leading solution in detecting risks for chronic diseases and we strongly believe that many customers in the United States will greatly benefit from the advantages of our technology in building more preventative, scalable, and efficient healthcare solutions. ” Says Teemu Suna, CEO and Founder of Nightingale Health.
The impact of the agreement on the continuous service to Nightingale Health’s revenue will depend on the number of orders, which are not defined in the agreement.
For further information, please contact:
Teemu Suna, CEO
ir@nightingalehealth.com
About Nightingale Health
Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.
Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com/
Tags:
